EGFR and glioblastoma: IDH and TERT promoter mutations, MGMT methylation, EGFR gene amplification, PTEN tumor suppressor gene deletion, ATRX mutation, and TP53 mutation, CDKN2A/B homozygous deletion mutation, as well as combined gain of entire chromosome 7 and loss of entire chromosome (+7/−10) are well-studied biomarkers for GBM [8,9].